FDA has flagged GLP-1 telehealth ads that describe compounded semaglutide or tirzepatide as generic, as the same as brand-name drugs, as having the same active ingredient, as clinically proven, or as made by an FDA-approved facility. FDA says compounded drugs are not FDA-approved. It sent waves of warning letters in September 2025, March 2026 and June 2026.
Published October 24, 2026. Updated October 24, 2026. Sourced from FDA statements, FDA warning letters and FDA's telehealth guidance page.
The encouraging news for telehealth brands is that FDA's concerns are specific and repeated, which makes them easy to audit. This guide lists the claims regulators flagged, the timeline of enforcement, and a practical review routine for websites, ads and social posts. It is a communications checklist, not legal advice.
Key points for telehealth marketers:
- FDA objects to equivalence claims, not to the existence of telehealth care
- Compounded drugs are not FDA-approved, and marketing copy must not suggest otherwise
- Product labels that name a company as the compounder must be accurate
- FDA has warned that continued violations can bring seizure or injunction
Table of contents
- Which claims did regulators flag in GLP-1 telehealth ads?
- What is the timeline of FDA enforcement?
- Which legal provisions do the letters cite?
- What can telehealth brands say instead?
- How should teams audit GLP-1 marketing pages?
- Frequently asked questions
Which claims did regulators flag in GLP-1 telehealth ads?
FDA flagged claims that make a compounded GLP-1 drug sound like an FDA-approved one. The agency's February 6, 2026 statement says promotional materials cannot call non-approved compounded products generic versions of approved drugs, cannot say they are the same as approved drugs, and cannot say they use the same active ingredient. The statement adds that companies also cannot say compounded drugs are clinically proven to produce results.
FDA's telehealth guidance page repeats those points and adds a claim about facilities: a company cannot say a compounded drug comes from an FDA-approved or FDA-licensed pharmacy, because FDA does not approve or license any facility.
| Claim FDA flagged | Why FDA objects | Safer approach |
|---|
| "Generic" semaglutide or tirzepatide | Generics are approved before marketing. Compounded drugs are not | Describe the product as compounded |
| "Same active ingredient" as a brand-name drug | FDA says the claim implies approval or review that has not happened | State plainly that the drug is compounded and not FDA-approved |
| "Clinically proven" results | FDA says compounded drugs are not shown to produce the same results as approved drugs | Avoid efficacy equivalence claims |
| Sourced from an FDA-approved or licensed pharmacy | FDA does not approve or license any facility | Name the compounder accurately and avoid approval wording |
| Product label naming the brand as compounder | FDA letters to MEDVi and SkinnyRx said the labels suggested a company was the compounder when it was not | Show the true compounder on labels and pages |
| "FDA approved ingredient combined with a vitamin" | An Altru Telehealth letter flagged wording of this kind as misleading about the formulation | Describe ingredients factually without implying review |
What is the timeline of FDA enforcement?
FDA enforcement on compounded GLP-1 promotion has run in several waves between September 2025 and June 2026. The sequence below uses FDA's own documents where available and law firm or press counts where noted.
- September 9, 2025: FDA and HHS announced a broad initiative on misleading direct-to-consumer drug advertising, and FDA later published warning letters to telehealth and compounding firms. Law firm counts of the September letters vary.
- February 6, 2026: FDA's commissioner announced the intent to restrict GLP-1 active ingredients used in non-approved compounded drugs that are mass-marketed, and restated the advertising rules quoted above.
- February 20, 2026: FDA issued warning letters to firms including MEDVi and SkinnyRx over equivalence claims and label representations.
- Early March 2026: Reuters reported 30 more warning letters to telehealth companies, according to a press summary.
- June 2026: FDA published 25 further warning letters, including the Altru Telehealth letter dated June 8, 2026, and launched a telehealth guidance page.
The law firm Sheppard Mullin counts the September 2025, March 2026 and June 2026 rounds as three major sets of letters in under a year. Each response deadline in the letters is 15 business days.
Which legal provisions do the letters cite?
The warning letters cite sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Under section 502(bb), a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular, according to the text of the SkinnyRx warning letter.
The letters add that compounded drugs have not been evaluated by FDA for safety, effectiveness or quality before marketing, which is the review that approved drugs receive. The Altru Telehealth letter asks for a written response to FDA's Office of Compounding Quality and Compliance within fifteen business days.
FDA's February statement also notes that entities which do not address violations may face legal action without further notice, including seizure and injunction.
What can telehealth brands say instead?
Telehealth brands can describe their service, their clinicians and the process of care, and they can describe compounded products as compounded. The FDA sources point to a clear pattern of safe wording.
- Say the medication is compounded and not FDA-approved
- Explain that FDA does not review compounded drugs for safety, effectiveness or quality before marketing, which is FDA's own wording
- Name the actual compounding pharmacy or outsourcing facility on labels and pages
- Describe the clinician evaluation and the ordering process rather than outcomes borrowed from brand-name trials
- Keep any claims about FDA-approved brand drugs tied to those products only
Brands that adopt this wording also tend to read better to patients, because it answers the first question most people have: what exactly am I being prescribed. Everything-PR analyzes the wider marketing playbook in Hims, Ro, and telehealth drug marketing, and the sector rulebook in its health tech PR guide.
How should teams audit GLP-1 marketing pages?
Teams should audit every page, ad, email and social post that mentions semaglutide, tirzepatide or liraglutide, because the letters were based on website reviews. A short routine keeps the work manageable.
Six-step audit checklist
- List every page and asset that names a GLP-1 drug or brand-name equivalent.
- Search for the words generic, same, identical, clinically proven and FDA-approved.
- Check each product image for a label that names a company that is not the compounder.
- Replace equivalence claims with plain statements that the drug is compounded and not FDA-approved.
- Confirm that the named compounder matches the pharmacy or facility that fills the order.
- Send the revised copy through legal and regulatory review and archive the final version.
Communications teams can also prepare a short holding statement for press and patients. A calm, factual explanation of what compounded means is the best answer to reporter questions about FDA letters.
Sources: FDA statement of February 6, 2026, FDA telehealth guidance page, FDA warning letter to MEDVi, FDA warning letter to SkinnyRx, and FDA warning letter to Altru Telehealth.
Related links: Hims, Ro, and telehealth drug marketing, Health Tech PR: Strategy, Rules, and Agencies, and 5W PR, creative and GEO agency.
